Magenta Therapeutics (MGTA) has an average buy rating among analysts, with a price target range of $2 to $20. (MT Newswires covers equity, commodity and...
Magenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
Magenta Therapeutics (MGTA) shares were down almost 10% on Monday afternoon after a series of price-target cuts. Mizuho Securities cut the price target to...
Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
| Address | 100 Technology Square Cambridge, Massachusetts 02139 |
| Phone | +1.857.242.0170 |
| Number of Employees | N/A |
| Recent SEC Filing | 08/04/2022 S-3 |
| President, Chief Executive Officer & Director | Jason Gardner |
| COO, CFO, Treasurer & Chief Accounting Officer | Stephen Frank Mahoney |
| Chief Scientific Officer & Head-Research | Lisa M. Olson |
| Chief Technical Officer | David Nichols |
| Price Open | $1.73 |
| Previous Close | $1.77 |
| 52 Week Range | $0.92 - 8.49 |
| Market Capitalization | $104.8 M |
| Shares Outstanding | 58.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.31 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -47.40% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
